Boehringer Ingelheim and Inventiva recently created a new collaboration that focuses on developing new therapies that could potentially treat Idiopathic Pulmonary Fibrosis (IPF).
This drug discovery collaboration will last for several years as they develop the treatments and licensing agreement. According to the agreement, the two companies will confirm a novel therapeutic concept for new IPF and similar fibrotic diseases.
“We are very proud to enter into this collaboration with Boehringer Ingelheim, a company well-reputed for its excellent research and development skills in the field of fibrosis, and particularly Idiopathic Pulmonary Fibrosis,” Pierre Broqua, Inventiva’s co-founder and CSO, said. “We plan, alongside developing our own pipeline, on pursuing our strategy of establishing collaborative research partnerships with the world’s biggest pharmaceutical companies. This new partnership further testifies to Inventiva’s expertise and contributes to strengthening our position as a leading and innovative actor in the field of fibrosis.”
With Inventiva’s knowledge and proprietary technologies, and Boehringer Ingelheim’s clinical development and drug discovery experience, the two new companies intend to make new therapeutic agents.
“We are enthusiastic about this partnership and look forward to collaborating with Inventiva’s team to develop a potential new breakthrough therapy for the treatment of Idiopathic Pulmonary Fibrosis,” Clive Wood, senior corporate vice president of discovery research at Boehringer Ingelheim, said. “We are impressed by Inventiva’s research and drug discovery competencies and deep knowledge of the field. We firmly believe that joining forces with Inventiva will enable us to foster translation of an aspirational new therapeutic concept into eagerly awaited new therapies for patients.”
